Filter By Industry
Filter By Tag

Newsroom

Families of Spinal Muscular Atrophy Press releases

21 - 30 of 32 Press Releases

Jan 18, 2012
Developing new therapies to treat and ultimately cure SMA is the driving force behind Families of SMA. To achieve this goal, Families of SMA aggressively invests in drug development research.

Jan 10, 2012
Nutrition Basics: Fostering Health and Growth for Spinal Muscular Atrophy is Families of SMA’s newest release of the SMA Care Series Booklets, which are provided free of charge to all SMA families, as well as SMA Care Providers worldwide.

Dec 19, 2011
Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study of ISIS-SMNRx in patients with spinal muscular atrophy (SMA). Isis is developing ISIS-SMNRx as a potential treatment for all types of SMA.

Oct 18, 2011
Awards to help develop new therapies for SMA. These new awards encompass $745,000 for the basic research portion of the $3 Million in new research funding that FSMA announced earlier this year.

Jul 20, 2011
The new funding awards will be allocated into three distinct research areas: 1)Basic Research to understand the disease, 2)Drug Discovery to develop new SMA therapies, and 3)Clinical Research to provide the means to test new drugs effectively.

May 19, 2011
First ever clinical trial approved for SMA with a novel drug specifically designed to treat the disease.

Feb 24, 2011
Boynton Beach residents Shaina and Adi Rappoport have served as the event organizers since 2002 when their son, Jacob, passed way from SMA (Spinal Muscular Atrophy) related complications. Jacob was nine months old.

Dec 30, 2010
As 2010 comes to a close, we wanted to thank you for your donations and efforts that have supported our research programs and family services.

Dec 29, 2010
In response to our October Request for Proposals (RFP) for new drug programs to develop therapies for Spinal Muscular Atrophy we received nine Letters of Intent for potential programs.

Dec 16, 2010
The MDA has committed to invest funds in the FSMA Quinazoline Program at Repligen Corporation to assist in advancing the program to an IND filing with the FDA. FSMA began the Quinazoline, or DcpS inhibitor RG3039, program in 2000.


Page: Prev 1 2 3 4 Next
Families of Spinal Muscular Atrophy RSS Feed